Targeting JNK-interacting-protein-1 (JIP1) sensitises osteosarcoma to doxorubicin.
Posthumadeboer J, van Egmond PW, Helder MN, de Menezes RX, Cleton-Jansen AM, Beliën JA, Verheul HM, van Royen BJ, Kaspers GJ, van Beusechem VW.
Posthumadeboer J, et al. Among authors: de menezes rx.
Oncotarget. 2012 Oct;3(10):1169-81. doi: 10.18632/oncotarget.600.
Oncotarget. 2012.
PMID: 23045411
Free PMC article.